Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 18/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.61 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2958646 | 0.91 | PTGER1 (1.00) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL13239359 | 0.86 | PTGER1 (0.91) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL13874500 | 0.86 | PTGER1 (0.78) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL2961468 | 0.85 | PTGER1 (0.77) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL4164060 | 0.85 | PTGER1 (0.77) | PTGER1CYP1A2CYP2C9 | |
| SCHEMBL2952676 | 0.85 | PTGER1 (0.84) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL4158460 | 0.84 | PTGER1 (0.76) | PTGER1CYP1A2CYP2C9 | |
| SCHEMBL4164627 | 0.83 | PTGER1 (0.74) | PTGER1CYP1A2CYP2C9 | |
| SCHEMBL4163185 | 0.83 | PTGER1 (0.73) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL13890168 | 0.83 | PTGER1 (0.73) | PTGER1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099177-A1 | PYRIDYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099177-A1 | PYRIDYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099177-A1 | PYRIDYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099177-A1 | PYRIDYL COMPOUNDS | CYP2C19, CYP4F3, C5 | PTGER1 180/4885CYP1A2 24/4885CYP2C9 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.